CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

9d ago, source:

Joseph Todisco, Chief Executive Officer of CorMedix commented, “CMS determination of TDAPA eligibility for DefenCath is a critical step toward ensuring this innovative preventative drug product is ...

CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)

13d ago, source:

DefenCath (taurolidine and heparin) is approved by the U.S. Food and Drug Administration (FDA) to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with kidney ...

CorMedix Shares Rise 6% After DefenCath Meets Payment Criteria

9d ago, source:

By Chris Wack CorMedix shares were up 6% to $5.73 after the company said that the Center for Medicare & Medicaid Services has determined that ...

Boeing adds a new outside firm

6d ago, source:

Boeing retained The Doerrer Group’s Paul Doerrer on March 7 to lobby on issues related to commercial planes, according to a disclosure filing.

DefenCath Now Available for Dialysis Patients to Prevent Catheter-Related Infections

14d ago, source: Monthly Prescribing Reference

“Today opens a new chapter for health care providers, offering them an opportunity to reduce the risk of CRBSIs in a patient population already vulnerable due to underlying kidney failure,” said ...

Rallying Cry: 3 Momentum Stocks Surfing Toward Even Greater Gains

on MSN ago, source:

According to Investopedia, “Momentum investing is a trading strategy in which investors buy securities that are rising and ...

CorMedix, Inc.: CorMedix Inc. Announces CMS Grants TDAPA to DefenCath

9d ago, source: Finanznachrichten

BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...